Bempedoic Acid (Nilemdo)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses bempedoic acid (Nilemdo), 180 mg, tablet, oral.
• Indication:
  • Primary hyperlipidemia
    • Nilemdo (bempedoic acid) is indicated for the reduction of low-density lipoprotein cholesterol(LDL-C) in adults with hyperlipidemia, i.e., heterozygous familial hypercholesterolemia (HeFH) and mixed dyslipidemias,
      • as an adjunct to diet, in combination with statins, with or without ezetimibe and PCSK9 inhibitors, or
      • as an adjunct to diet, as monotherapy in patients who cannot tolerate recommended statin therapy, with or without ezetimibe and PCSK9 inhibitors.
  • Prevention of cardiovascular events
    • Nilemdo is indicated to reduce the risk of adverse cardiovascular events, defined as cardiovascular death, myocardial infarction, stroke, or coronary revascularisation, in adults at increased risk for these events.
    • Nilemdo should be used with statin drug therapy, as tolerated, with or without ezetimibe and PCSK9 inhibitors. In patients unable to take statins at any dose, Nilemdo may be used as monotherapy, or combined with ezetimibe and/or PCSK9 inhibitors, as appropriate.